RecruitingNCT05318196

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

Sponsor

University Hospital, Toulouse

Enrollment

5,000 participants

Start Date

Sep 5, 2022

Study Type

OBSERVATIONAL

Conditions

Cancer Metabolic Disease Chronic Kidney Diseases Acute Kidney Injury Solid-organ Transplantation Immune Diseases

Summary

Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood, urine, and tissue samples from kidney patients to build a database that helps scientists predict who will develop, worsen, or have complications from kidney disease, including in transplant patients. **You may be eligible if...** - You are over 18 years old - You have kidney disease or are at risk of developing it - You are followed by the Nephrology or Transplant department at the University Hospital of Toulouse, France **You may NOT be eligible if...** - You do not consent to participate - You or your family are unable to give consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBiological samples collection

SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications). Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol. Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care.